Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Arsenic trioxide.

Mark R Litzow1

  • 1Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA. litzow.mark@mayo.edu

Expert Opinion on Pharmacotherapy
|June 24, 2008
PubMed
Summary
This summary is machine-generated.

Arsenic trioxide is effective for acute promyelocytic leukemia (APL). Further research is needed to determine its role in treating other cancers, while careful patient management minimizes side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

American journal of hematology·2026
Same author

Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies.

Acta haematologica·2026
Same author

Outcomes of hemophagocytic lymphohistiocytosis in acute myeloid leukemia: the 3-site Mayo Clinic experience.

Blood neoplasia·2026
Same author

Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Leukemia & lymphoma·2026
Same author

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.

Blood cancer journal·2026
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

CURRENT ADVANCES IN PHARMACOTHERAPEUTIC STRATEGIES FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Toxicology

Background:

  • Arsenic, an ancient compound, demonstrates significant efficacy in treating relapsed acute promyelocytic leukemia (APL).
  • Its success in APL has prompted investigations into its potential use for other cancer types.

Purpose of the Study:

  • To elucidate the mechanism of action of arsenic in cancer treatment.
  • To summarize the therapeutic development of arsenic in APL and other malignancies.

Main Methods:

  • Conducted a comprehensive 20-year literature search across major databases: MEDLINE, EMBASE, and Web of Science.
  • Systematically reviewed clinical trials and research on arsenic's efficacy and safety.

Main Results:

  • Clinical trials confirm the therapeutic benefit of arsenic trioxide in APL treatment.

Related Experiment Videos

  • The efficacy of arsenic trioxide in other malignant disorders is still under investigation.

    • Conclusions:

    • Arsenic trioxide is a validated treatment for APL.
    • Its application in other cancers requires further study.
    • Effective clinical management is crucial for mitigating potential side effects of arsenic trioxide therapy.